These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21421311)

  • 1. Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome.
    Maletic M; Leeman A; Szymonifka M; Mundt SS; Zokian HJ; Shah K; Dragovic J; Lyons K; Thieringer R; Vosatka AH; Balkovec J; Waddell ST
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2568-72. PubMed ID: 21421311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
    Gu X; Dragovic J; Koo GC; Koprak SL; LeGrand C; Mundt SS; Shah K; Springer MS; Tan EY; Thieringer R; Hermanowski-Vosatka A; Zokian HJ; Balkovec JM; Waddell ST
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5266-9. PubMed ID: 16185866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Aster SD; Graham DW; Kharbanda D; Patel G; Ponpipom M; Santorelli GM; Szymonifka MJ; Mundt SS; Shah K; Springer MS; Thieringer R; Hermanowski-Vosatka A; Wright SD; Xiao J; Zokian H; Balkovec JM
    Bioorg Med Chem Lett; 2008 May; 18(9):2799-804. PubMed ID: 18434143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Olson S; Aster SD; Brown K; Carbin L; Graham DW; Hermanowski-Vosatka A; LeGrand CB; Mundt SS; Robbins MA; Schaeffer JM; Slossberg LH; Szymonifka MJ; Thieringer R; Wright SD; Balkovec JM
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4359-62. PubMed ID: 16039856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
    Roche D; Carniato D; Leriche C; Lepifre F; Christmann-Franck S; Graedler U; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E
    Bioorg Med Chem Lett; 2009 May; 19(10):2674-8. PubMed ID: 19395260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and 11β hydroxysteroid dehydrogenase 1 inhibition of thiazolidine derivatives with an adamantyl group.
    Kwon SW; Kang SK; Lee JH; Bok JH; Kim CH; Dal Rhee S; Jung WH; Kim HY; Bae MA; Song JS; Ha DC; Cheon HG; Kim KY; Ahn JH
    Bioorg Med Chem Lett; 2011 Jan; 21(1):435-9. PubMed ID: 21093259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders.
    Yoon DS; Wu SC; Seethala R; Golla R; Nayeem A; Everlof JG; Gordon DA; Hamann LG; Robl JA
    Bioorg Med Chem Lett; 2014 Nov; 24(21):5045-9. PubMed ID: 25266782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mono-carbonyl curcumin analogues as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
    Lin H; Hu GX; Guo J; Ge Y; Liang G; Lian QQ; Chu Y; Yuan X; Huang P; Ge RS
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4362-6. PubMed ID: 23800686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
    Yang H; Dou W; Lou J; Leng Y; Shen J
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substituted phenyl triazoles as selective inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1.
    Sun W; Maletic M; Mundt SS; Shah K; Zokian H; Lyons K; Waddell ST; Balkovec J
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2141-5. PubMed ID: 21334894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent and novel 11β-HSD1 inhibitors identified from shape and docking based virtual screening.
    Xia G; Xue M; Liu L; Yu J; Liu H; Li P; Wang J; Li Y; Xiong B; Shen J
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5739-44. PubMed ID: 21873057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Odermatt A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1477-83. PubMed ID: 19780703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the discovery of 11beta-HSD1 inhibitors.
    Boyle CD
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors.
    Stanetty C; Czollner L; Koller I; Shah P; Gaware R; Cunha TD; Odermatt A; Jordis U; Kosma P; Classen-Houben D
    Bioorg Med Chem; 2010 Nov; 18(21):7522-41. PubMed ID: 20851614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.
    Richards S; Sorensen B; Jae HS; Winn M; Chen Y; Wang J; Fung S; Monzon K; Frevert EU; Jacobson P; Sham H; Link JT
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6241-5. PubMed ID: 17000111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of cyclicsulfonamide derivatives with an acetamide group as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
    Kim SH; Kwon SW; Chu SY; Lee JH; Narsaiah B; Kim CH; Kang SK; Kang NS; Rhee SD; Bae MA; Ahn SH; Ha DC; Kim KY; Ahn JH
    Chem Pharm Bull (Tokyo); 2011; 59(1):46-52. PubMed ID: 21212546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening.
    Lagos CF; Vecchiola A; Allende F; Fuentes CA; Tichauer JE; Valdivia C; Solari S; Campino C; Tapia-Castillo A; Baudrand R; Villarroel P; Cifuentes M; Owen GI; Carvajal CA; Fardella CE
    Mol Cell Endocrinol; 2014 Mar; 384(1-2):71-82. PubMed ID: 24447464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of 3,8-substituted 1,2,4-triazolopyridines as potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1).
    Wang H; Robl JA; Hamann LG; Simpkins L; Golla R; Li YX; Seethala R; Zvyaga T; Gordon DA; Li JJ
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4146-9. PubMed ID: 21689935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors.
    Neelamkavil SF; Boyle CD; Chackalamannil S; Greenlee WJ; Zhang L; Terracina G
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4563-5. PubMed ID: 19625185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.